Author's response to reviews

Title: Podocalyxin is a marker of poor prognosis in colorectal cancer

Authors:

Tuomas Kaprio (tuomas.kaprio@helsinki.fi)
Christian Fermér (christian.fermer@fdab.com)
Jaana Hagström (jaana.hagstrom@hus.fi)
Harri Mustonen (harri.mustonen@helsinki.fi)
Camilla Böckelman (camilla.bockelman@helsinki.fi)
Olle Nilsson Nilsson (olle.nilsson@fdab.com)
Caj Haglund (caj.haglund@hus.fi)

Version: 3
Date: 5 March 2014

Author's response to reviews: see over
March, 5, 2014

Dear Editor-in-chief,

Enclosed please find our two revised manuscripts ”Podocalyxin is a marker of poor prognosis in colorectal cancer” and “A comparative study of two PODXL antibodies in 840 colorectal cancer patients”, both under MS: 1596918575116611.

We thank the referees for their valuable comments. We have responded to all their comments and have made corresponding changes to the manuscripts. We sincerely hope that our revised manuscripts will be suitable for publication in BMC Cancer, and that they will be published as two separate parallel papers, in the same issue of your journal as suggested by the referee.

Yours sincerely,

Tuomas Kaprio, M.D.   Caj Haglund, M.D. , Ph.D.
FIN-00290 HUS, Helsinki, FINLAND   FIN-00290 HUS, Helsinki, FINLAND
Phone: +358 505910353   Phone:+358 9 47172427
E-mail: tuomas.kaprio@helsinki.fi  Email: caj.haglund@hus.fi

Enclosed:
-Response to the referees comments
-Revised manuscript: Podocalyxin is a marker of poor prognosis in colorectal cancer
 -version with the changes highlighted
-Revised manuscript: “A comparative study of two PODXL antibodies in 840 colorectal cancer patients”
 -version with the changes highlighted